Zheming Wang

Title: Zheming Wang: Innovator in Pharmaceutical Chemistry

Introduction

Zheming Wang is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as NAMPT inhibitors. With a total of 3 patents, his work is paving the way for potential advancements in chemotherapy treatments.

Latest Patents

Wang's latest patents include innovative compounds that have the potential to address various diseases associated with abnormal NAD expression. One of his notable inventions is a pyrrolidine derivative, which is designed to function as an NAMPT inhibitor. This compound features a parent structure of pyrrolidine, with a pyridinylurea group attached via an intermediate aliphatic chain. The optimized structure enhances water solubility and simplifies the synthesis process, making it more suitable for industrial production.

Another significant patent is the pyridinylcyanoguanidine derivative, which also acts as an NAMPT inhibitor. This compound includes a cyanoguanidine structure attached to piperazine or pyrrolidine, further optimizing the interaction with NAMPT. The introduction of this structure not only improves the compound's affinity but also addresses the water solubility issues associated with previous inhibitors.

Career Highlights

Throughout his career, Zheming Wang has worked with various companies, including Rushi Biotech (Hangzhou) Co., Ltd. His expertise in pharmaceutical chemistry has allowed him to contribute to the development of innovative solutions in the industry.

Collaborations

Wang has collaborated with several professionals in his field, including Hao Tan. These partnerships have facilitated the exchange of ideas and advancements in their shared research interests.

Conclusion

Zheming Wang's contributions to pharmaceutical chemistry, particularly through his innovative patents, highlight his role as a significant inventor in the field. His work continues to inspire advancements in treatments for diseases related to abnormal NAD expression.